Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1

Interventions

Cytarabine 30Filgrastim 12Daunorubicin 11Busulfan 11Idarubicin 10Peripheral Blood Stem Cell Transplantation 9Etoposide 9fludarabine phosphate 8Mitoxantrone 7Methotrexate 7Gemtuzumab 7sargramostim 6Cyclosporine 6Decitabine 5Cyclophosphamide 5Azacitidine 5Antilymphocyte Serum 5tipifarnib 4alvocidib 4Tacrolimus 4Whole-Body Irradiation 3Vorinostat 3Radiotherapy 3Mycophenolic Acid 3Injections 3Granulocyte Colony-Stimulating Factor 3Clofarabine 3Biopsy 3merphos 2entinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myelomonocytic, Acute × Idoxuridine × Clear all
NCT00003405 2021-10-14

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Rush University Medical Center

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡